Redcare Pharmacy NV Posts Robust Q3 Growth Amid Digital‑Prescription Momentum
Redcare Pharmacy NV (ISIN NL0012044747, WKN A2AR94) has announced that its third‑quarter revenue rose by 25 % to €719 million, up from €575 million a year earlier. The figure was released in a press statement issued on Monday, 6 October 2025, and was corroborated by several market‑watching outlets, including Retail‑News.de, Wallstreet‑Online.de, and Finanzen.ch.
Revenue and Market Position
The jump in sales is largely attributed to the expanding e‑prescription market in Germany, which has seen increased regulatory support and higher consumer adoption. With the total sales of the company for the year to date now standing at €2.15 billion, Redcare is cementing its status as Europe’s largest online pharmacy by revenue.
The company’s price‑to‑earnings ratio of –43.26 reflects the significant negative earnings attributable to aggressive investment in technology, marketing and fulfilment infrastructure. Nevertheless, the market has responded positively; the stock closed at €78.15 on 2 October, a +8 % gain in the first trading session after the announcement, bringing the share price near a €175 target set by Baader Bank. While UBS has issued a “Sell” recommendation, the consensus from other analysts remains largely bullish.
Strategic Drivers
- E‑Prescription Expansion – Redcare’s core platform now supports a growing share of prescription orders that can be processed electronically, reducing order processing time and improving customer experience.
- Diversified Product Portfolio – The company continues to broaden its catalogue beyond pharmaceuticals into pharmacy‑related beauty, personal care and natural health products, creating cross‑selling opportunities.
- Pan‑European Reach – With logistics centres across the continent, the firm can deliver to a wide customer base quickly, a critical advantage in the highly competitive online‑pharmacy sector.
Investor Sentiment and Analyst Outlook
- Baader Bank reiterated its “Buy” rating, keeping the 2025 target price at €175 and citing the company’s “stable figures” in a challenging market environment.
- UBS issued a “Sell” note, reflecting concerns over valuation and negative earnings.
- Wallstreet‑Online.de highlighted the “strong rebound potential” of the share after a prolonged 40 % decline over the last twelve months, suggesting a potential turnaround for the MDAX‑listed stock.
Financial Snapshot
| Metric | Value |
|---|---|
| Current Close (02‑Oct‑2025) | €78.15 |
| 52‑Week High | €171.4 |
| 52‑Week Low | €69.65 |
| Market Cap | €1.58 billion |
| Q3 Revenue | €719 million |
| YoY Q3 Growth | 25 % |
Conclusion
Redcare Pharmacy’s latest quarterly results underscore the firm’s successful execution of a digital‑prescription strategy that has translated into measurable revenue growth. Despite a historically negative earnings profile and divergent analyst opinions, the company’s market position and continued expansion into complementary product lines appear to be bolstering investor confidence. The forthcoming full year outlook will likely be scrutinised to assess whether the momentum can be sustained beyond the current quarter’s surge.
